Literature DB >> 11405903

Diagnosis and treatment of severe pediatric pulmonary hypertension.

D Ivy1.   

Abstract

Advances in the treatment of pulmonary hypertension during the past decade have dramatically improved patient survival. Many of these advances are based on improved understanding of the vascular biology of the normal and hypertensive pulmonary circulations. Pulmonary hypertension is an important determinant of morbidity and mortality in patients with many pediatric diseases, including congenital heart disease. This article describes current diagnostic strategies and treatments for patients with primary and secondary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405903     DOI: 10.1097/00045415-200107000-00009

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  6 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Pulmonary hypertension--a new manifestation of mitochondrial disease.

Authors:  A R Barclay; G Sholler; J Christodolou; A Shun; S Arbuckle; S Dorney; M O Stormon
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Assessment of pulmonary arterial hypertension and vascular resistance by measurements of the pulmonary arterial flow velocity curve in the absence of a measurable tricuspid regurgitant velocity in childhood congenital heart disease.

Authors:  Ayhan Cevik; Serdar Kula; Rana Olgunturk; F Sedef Tunaoglu; A Deniz Oguz; Berna Saylan; Erman Cilsal; Cihat Sanli
Journal:  Pediatr Cardiol       Date:  2012-10-05       Impact factor: 1.655

5.  Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.

Authors:  S C Apostolopoulou; A Manginas; D V Cokkinos; S Rammos
Journal:  Heart       Date:  2005-03-10       Impact factor: 5.994

Review 6.  Pediatric lung transplantation: promise being realized.

Authors:  Carol Conrad; David N Cornfield
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.